# name
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based
                malaria vaccines

# metadata.dc.description.abstract[].value
Sanaria Inc. has developed methods to manufacture, purify and
                cryopreserve aseptic Plasmodium falciparum (Pf) sporozoites
                (SPZ), and is using this platform technology to develop an
                injectable PfSPZ-based vaccine that provides high-grade, durable
                protection against infection with Pf malaria. Several candidate
                vaccines are being developed and tested, including PfSPZ
                Vaccine, in which the PfSPZ are attenuated by irradiation,
                PfSPZ-CVac, in which fully infectious PfSPZ are attenuated in
                vivo by concomitant administration of an anti-malarial drug, and
                PfSPZ-GA1, in which the PfSPZ are attenuated by gene knockout.
                Forty-three research groups in 15 countries, organized as the
                International PfSPZ Consortium (I-PfSPZ-C), are collaborating to
                advance this program by providing intellectual, clinical, and
                financial support. Fourteen clinical trials of these products
                have been completed in the USA, Europe and Africa, two are
                underway and at least 12 more are planned for 2015-2016 in the
                US (four trials), Germany (2 trials), Tanzania, Kenya, Mali,
                Burkina Faso, Ghana and Equatorial Guinea. Sanaria anticipates
                application to license a first generation product as early as
                late 2017, initially to protect adults, and a year later to
                protect all persons >6 months of age for at least six months.
                Improved vaccine candidates will be advanced as needed until the
                following requirements have been met: long-term protection
                against natural transmission, excellent safety and tolerability,
                and operational feasibility for population-wide administration.
                Here we describe the three most developed whole PfSPZ vaccine
                candidates, associated clinical trials, initial plans for
                licensure and deployment, and long-term objectives for a final
                product suitable for mass administration to achieve regional
                malaria elimination and eventual global eradication.

# metadata.dc.relation.isformatof[].value
Reproducció del document publicat a:
                http://dx.doi.org/10.1016/j.vaccine.2015.09.096

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based
                malaria vaccines